Gel-One Hyaluronate is an injectable hyaluronate gel approved for the treatment of osteoarthritis of the knee that does not respond to other conservative treatments. It is the first low-volume viscosupplement injectable available in a single-injection formula.
The highly purified, high viscosity Gel-One Hyaluronate formula requires less volume for effective pain relief with no reports of pseudosepsis (severe acute inflammatory responses) in the clinical trial.
In a major study of 379 randomized patients1 (248 receiving Gel-One Hyaluronate), the findings are clear:
- Gel-One Hyaluronate demonstrated superior pain relief from baseline at 13 weeks when compared with a PBS control
- Patients receiving Gel-One Hyaluronate experienced, on average, a nearly 40% reduction in pain from baseline (28 mm reduction in WOMAC pain on a 100 mm VAS scale).
- Zero incidents of pseudosepsis or any other severe adverse events were reported with Gel-OneHyaluronate treatment.
- Side effects were as expected, and most commonly included joint swelling, joint effusion and joint pain.